Sivik Global Healthcare LLC Invests $1.95 Million in Bruker Corporation $BRKR

Sivik Global Healthcare LLC bought a new position in shares of Bruker Corporation (NASDAQ:BRKR) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 60,000 shares of the medical research company’s stock, valued at approximately $1,949,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Amundi grew its stake in shares of Bruker by 373.3% during the first quarter. Amundi now owns 42,503 shares of the medical research company’s stock valued at $1,774,000 after purchasing an additional 33,522 shares during the last quarter. Vaughan Nelson Investment Management L.P. boosted its position in Bruker by 71.2% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,293,645 shares of the medical research company’s stock valued at $53,298,000 after buying an additional 537,845 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Bruker by 35.6% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 40,450 shares of the medical research company’s stock worth $1,717,000 after acquiring an additional 10,624 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in shares of Bruker by 60.8% during the second quarter. Public Employees Retirement System of Ohio now owns 55,672 shares of the medical research company’s stock valued at $2,294,000 after acquiring an additional 21,043 shares during the period. Finally, State of New Jersey Common Pension Fund D lifted its stake in shares of Bruker by 39.0% during the second quarter. State of New Jersey Common Pension Fund D now owns 51,828 shares of the medical research company’s stock valued at $2,135,000 after acquiring an additional 14,547 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Price Performance

BRKR opened at $52.67 on Wednesday. The stock has a market cap of $8.00 billion, a P/E ratio of -329.19, a P/E/G ratio of 6.64 and a beta of 1.17. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $64.64. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. The company has a fifty day simple moving average of $45.20 and a 200 day simple moving average of $39.45.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. During the same period in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, research analysts expect that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s payout ratio is presently -125.00%.

Insider Transactions at Bruker

In related news, Director John A. Ornell sold 6,233 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the transaction, the director directly owned 35,212 shares in the company, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 27.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Guggenheim boosted their price objective on Bruker from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. TD Cowen increased their price objective on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a report on Tuesday, November 4th. Redburn Partners set a $60.00 target price on shares of Bruker in a report on Thursday, November 20th. Finally, Barclays increased their price target on Bruker from $45.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $51.50.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.